A Phase 2 interventional study of brentuximab vedotin and bendamustine in Hodgkin Disease and Peripheral T Cell Lymphoma, sponsored by Seagen Inc.. Completed at 54 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-11.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 15th largest by enrollment, is one of 7 that started in 2012, is one of 41 in phase 2, and was the 17th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
22 studies in Hodgkin Disease by Pfizer: none open now, none under way, none of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 22 studies in Hodgkin Disease by Pfizer, this one is the 6th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2012, is one of 5 in phase 2, and was the 12th registered.
Pfizer’s Hodgkin Disease studies by the year they started, since 2000.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among Pfizer’s 22 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.
This study is designed to evaluate the efficacy and tolerability of brentuximab vedotin as monotherapy and in combination with other agents as frontline therapy. There are 6 parts of the study. The population to be studied includes treatment-naïve patients with classical Hodgkin lymphoma (HL) or treatment-naïve patients with CD30-expressing peripheral T-cell lymphoma (PTCL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Unsuitable or unfit for initial conventional combination chemotherapy for HL (Part E) or CD30-expressing PTCL due to the presence of comorbidity-factors, as documented by:
Exclusion Criteria:
Part D only:
Parts D, E, and F only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: brentuximab vedotin
Drug: brentuximab vedotin · Drug: dacarbazine
Drug: brentuximab vedotin · Drug: bendamustine
Drug: brentuximab vedotin · Drug: nivolumab
Drug: brentuximab vedotin
Drug: brentuximab vedotin
1.8 mg/kg every 3 weeks by IV infusion
Also known as: Adcetris; SGN-35
70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle
375 mg/m\^2 every 3 weeks by IV infusion
3 mg/kg every 3 weeks by IV infusion
Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C)
Objective response rate (ORR) per investigator was defined as the percentage of subjects with complete response (CR) or partial response (PR) through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Parts A, B, and C the response was assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).
Time frame: Up to 81 months
ORR According to the Lugano Classification Revised Staging System for Nodal Non-Hodgkin and Hodgkin Lymphomas (Lugano Criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Part D)
Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Part D, the response was assessed using the Lugano Classification Revised Staging System for nodal non-Hodgkin and cHL (Lugano criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC).
Time frame: Up to 60 months
ORR According to Modified Lugano Criteria Per Blinded Independent Central Review (BICR) (Parts E and F)
Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Parts E and F, the response was assessed per blinded independent central review (BICR) using the modified Lugano criteria.
Time frame: Up to 31 months
Number of Participants With Adverse Events
A treatment-emergent AE (TEAE) is defined as a newly occurring or worsening AE after the first dose of any study drug component. Treatment-related AEs are defined as treatment-emergent AEs that are determined by the investigator to be related to the treatment on study. TEAEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). The CTCAE displays Grades 1 through 5, where Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe or medically significant but not immediately life-threatening, Grade 4: Life-threatening consequences, Grade 5: Death related to AE.
Time frame: Up to 122 months
Number of Participants With Laboratory Abnormalities
Laboratory values were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). The CTCAE displays Grades 1 through 5, where Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe or medically significant but not immediately life-threatening, Grade 4: Life-threatening consequences, Grade 5: Death related to AE.
Time frame: Up to 30 months
Complete Response Rate
Complete response rate is defined as the percentage of patients with CR
Time frame: Up to 81 months
Duration of Complete Response
Duration of CR per investigator was defined as the time from start of the first documentation of CR to the first documentation of tumor progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.
Time frame: Up to 81 months
Duration of Objective Response
Duration of response per investigator was defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression (PD) based on radiographic evidence of progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.
Time frame: Up to 81 months
Progression-free Survival
Progression-free survival (PFS) per investigator was defined as the time from start of study treatment to first documentation of tumor progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.
Time frame: Up to 83 months
Disease Control Rate
Disease control rate (DCR) per investigator was defined as the percentage of subjects with CR, PR, or SD, per investigator assessment of best clinical response per Cheson 2007. For Parts E and F, the assessment was per BICR.
Time frame: Up to 81 months
ORR According to Lugano Criteria Per BICR (Parts E and F)
Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment.
Time frame: Up to 31 months
B Symptom Resolution Rate
B symptom resolution rate per investigator was defined as the percentage of subjects with lymphoma-related B symptoms at baseline who achieved resolution of all B symptoms at any time during the treatment period.
Time frame: Up to 42 weeks
Number of Participants With Brentuximab Vedotin Antitherapeutic Antibodies (ATA)
Time frame: Up to 30 months
Number of Participants With Nivolumab Antitherapeutic Antibodies (ATA) (Part D Only)
Time frame: Up to 30 months
Overall Survival (Parts E and F Only)
Overall survival (OS) per investigator was defined as the time from date of enrollment to date of death due to any cause.
Time frame: Up to 44 months
| Milestone | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| Started | 28 | 22 | 22 | 21 | 31 | 7 |
| Received at least one dose of study drug | 27 | 22 | 20 | 21 | 30 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 28 | 22 | 22 | 21 | 31 | 7 |
| Withdrew: Patient withdrawal of consent | 4 | 2 | 4 | 3 | 2 | 0 |
| Withdrew: Lost to follow-up | 3 | 3 | 0 | 2 | 1 | 0 |
| Withdrew: Death | 13 | 9 | 12 | 4 | 10 | 5 |
| Withdrew: Received treatment past data cutoff of up to 16 doses of bv. aes collected until end of study. | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Pi decision | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Change in performance status | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor terminated enrollment into part c | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Sponsor direction | 7 | 8 | 5 | 12 | 16 | 1 |
Objective response rate (ORR) per investigator was defined as the percentage of subjects with complete response (CR) or partial response (PR) through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Parts A, B, and C the response was assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).
| Percentage of participants | Part A | Part B | Part C |
|---|---|---|---|
| Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C) | 93 (75.7 to 99.1) | 95 (77.2 to 99.9) | 85 (62.1 to 96.8) |
Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Part D, the response was assessed using the Lugano Classification Revised Staging System for nodal non-Hodgkin and cHL (Lugano criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC).
| Percentage of participants | Part D |
|---|---|
| ORR According to the Lugano Classification Revised Staging System for Nodal Non-Hodgkin and Hodgkin Lymphomas (Lugano Criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Part D) | 86 (63.7 to 97.0) |
Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Parts E and F, the response was assessed per blinded independent central review (BICR) using the modified Lugano criteria.
| Percentage of participants | Part E | Part F |
|---|---|---|
| ORR According to Modified Lugano Criteria Per Blinded Independent Central Review (BICR) (Parts E and F) | 60 (40.6 to 77.3) | 43 (9.9 to 81.6) |
A treatment-emergent AE (TEAE) is defined as a newly occurring or worsening AE after the first dose of any study drug component. Treatment-related AEs are defined as treatment-emergent AEs that are determined by the investigator to be related to the treatment on study. TEAEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). The CTCAE displays Grades 1 through 5, where Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe or medically significant but not immediately life-threatening, Grade 4: Life-threatening consequences, Grade 5: Death related to AE.
| Participants | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| Any TEAE | 27 | 22 | 20 | 21 | 30 | 7 |
| Treatment-related TEAE | 25 | 22 | 19 | 18 | 24 | 6 |
| Any grade 3 or higher TEAE | 17 | 10 | 18 | 16 | 18 | 7 |
| Treatment-related grade 3 or higher TEAE | 13 | 9 | 16 | 12 | 8 | 4 |
| Any treatment-emergent (TE) serious adverse event (SAE) | 5 | 4 | 13 | 4 | 14 | 4 |
| Treatment-related TE SAE | 3 | 3 | 9 | 0 | 3 | 1 |
| TEAE leading to treatment discontinuation | 11 | 11 | 12 | 5 | 9 | 3 |
| Treatment-related TEAE leading to treatment discontinuation | 11 | 9 | 8 | 2 | 5 | 2 |
| TEAE leading to death | 0 | 0 | 3 | 1 | 4 | 2 |
| Treatment-related TEAE leading to death | 0 | 0 | 0 | 0 | 1 | 1 |
Laboratory values were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). The CTCAE displays Grades 1 through 5, where Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe or medically significant but not immediately life-threatening, Grade 4: Life-threatening consequences, Grade 5: Death related to AE.
| Participants | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| Hemoglobin High, Grade 1 | 2 | 1 | 0 | 1 | 1 | 0 |
| Hemoglobin High. Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin High. Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin High. Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin Low, Grade 1 | 10 | 6 | 10 | 9 | 13 | 4 |
| Hemoglobin Low, Grade 2 | 5 | 6 | 6 | 5 | 6 | 1 |
| Hemoglobin Low, Grade 3 | 1 | 0 | 1 | 2 | 0 | 0 |
| Hemoglobin Low, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes Low, Grade 1 | 2 | 3 | 2 | 3 | 5 | 4 |
| Leukocytes Low, Grade 2 | 3 | 3 | 5 | 3 | 1 | 1 |
| Leukocytes Low, Grade 3 | 0 | 1 | 5 | 1 | 1 | 0 |
| Leukocytes Low, Grade 4 | 0 | 0 | 1 | 0 | 0 | 0 |
| Lymphocytes High, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes High, Grade 2 | 0 | 0 | 0 | 1 | 2 | 1 |
| Lymphocytes High, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes High, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes Low, Grade 1 | 0 | 0 | 0 | 0 | 7 | 0 |
| Lymphocytes Low, Grade 2 | 4 | 7 | 2 | 6 | 7 | 2 |
| Lymphocytes Low, Grade 3 | 6 | 2 | 6 | 2 | 1 | 2 |
| Lymphocytes Low, Grade 4 | 0 | 0 | 9 | 1 | 0 | 0 |
| Neutrophils Low, Grade 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Neutrophils Low, Grade 2 | 3 | 4 | 5 | 2 | 2 | 1 |
| Neutrophils Low, Grade 3 | 2 | 1 | 3 | 2 | 2 | 2 |
| Neutrophils Low, Grade 4 | 0 | 2 | 1 | 1 | 1 | 0 |
| Platelets Low, Grade 1 | 4 | 2 | 8 | 3 | 5 | 2 |
| Platelets Low, Grade 2 | 2 | 1 | 2 | 1 | 0 | 0 |
| Platelets Low, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets Low, Grade 4 | 0 | 0 | 0 | 1 | 0 | 0 |
| Alanine Aminotransferase High, Grade 1 | 8 | 9 | 6 | 16 | 7 | 0 |
| Alanine Aminotransferase High, Grade 2 | 4 | 1 | 0 | 0 | 0 | 0 |
| Alanine Aminotransferase High, Grade 3 | 1 | 0 | 0 | 2 | 0 | 0 |
| Alanine Aminotransferase High, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin Low, Grade 1 | 8 | 6 | 9 | 9 | 6 | 3 |
| Albumin Low, Grade 2 | 3 | 3 | 5 | 6 | 4 | 0 |
| Albumin Low, Grade 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Albumin Low, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline Phosphatase High, Grade 1 | 10 | 10 | 5 | 4 | 12 | 3 |
| Alkaline Phosphatase High, Grade 2 | 3 | 0 | 2 | 4 | 0 | 0 |
| Alkaline Phosphatase High, Grade 3 | 1 | 0 | 0 | 1 | 0 | 0 |
| Alkaline Phosphatase High, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Amylase High, Grade 1 | 0 | 0 | 0 | 5 | 0 | 0 |
| Amylase High, Grade 2 | 0 | 0 | 0 | 2 | 0 | 0 |
| Amylase High, Grade 3 | 0 | 0 | 0 | 3 | 0 | 0 |
| Amylase High, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase High, Grade 1 | 14 | 8 | 8 | 16 | 9 | 0 |
| Aspartate Aminotransferase High, Grade 2 | 1 | 1 | 1 | 1 | 1 | 0 |
| Aspartate Aminotransferase High, Grade 3 | 2 | 0 | 0 | 1 | 1 | 0 |
| Aspartate Aminotransferase High, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium Corrected for Albumin High, Grade 1 | 1 | 0 | 1 | 2 | 6 | 1 |
| Calcium Corrected for Albumin High, Grade 2 | 1 | 0 | 0 | 2 | 0 | 0 |
| Calcium Corrected for Albumin High, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium Corrected for Albumin High, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium Corrected for Albumin Low, Grade 1 | 3 | 0 | 1 | 1 | 2 | 2 |
| Calcium Corrected for Albumin Low, Grade 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Calcium Corrected for Albumin Low, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium Corrected for Albumin Low, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine High, Grade 1 | 20 | 14 | 12 | 12 | 18 | 3 |
| Creatinine High, Grade 2 | 2 | 1 | 2 | 2 | 1 | 0 |
| Creatinine High, Grade 3 | 0 | 1 | 0 | 1 | 0 | 0 |
| Creatinine High, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glomerular Filtration Rate, Estimated Low, Grade 1 | 0 | 0 | 0 | 0 | 2 | 1 |
| Glomerular Filtration Rate, Estimated Low, Grade 2 | 0 | 0 | 0 | 0 | 11 | 2 |
| Glomerular Filtration Rate, Estimated Low, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glomerular Filtration Rate, Estimated Low, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose High, Grade 1 | 15 | 13 | 12 | 12 | 11 | 3 |
| Glucose High, Grade 2 | 10 | 6 | 3 | 5 | 8 | 2 |
| Glucose High, Grade 3 | 2 | 2 | 1 | 4 | 2 | 0 |
| Glucose High, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose Low, Grade 1 | 0 | 1 | 0 | 1 | 1 | 0 |
| Glucose Low, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose Low, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose Low, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lipase High, Grade 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Lipase High, Grade 2 | 0 | 0 | 1 | 2 | 0 | 0 |
| Lipase High, Grade 3 | 0 | 0 | 0 | 2 | 0 | 0 |
| Lipase High, Grade 4 | 0 | 0 | 0 | 2 | 0 | 0 |
| Phosphate Low, Grade 1 | 9 | 8 | 2 | 7 | 0 | 0 |
| Phosphate Low, Grade 2 | 2 | 5 | 3 | 6 | 4 | 0 |
| Phosphate Low, Grade 3 | 2 | 0 | 4 | 2 | 0 | 0 |
| Phosphate Low, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium High, Grade 1 | 1 | 1 | 0 | 0 | 1 | 0 |
| Potassium High, Grade 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| Potassium High, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium High, Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 |
| Potassium Low, Grade 1 | 6 | 5 | 5 | 8 | 1 | 2 |
| Potassium Low, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium Low, Grade 3 | 2 | 0 | 3 | 1 | 2 | 0 |
| Potassium Low, Grade 4 | 0 | 0 | 1 | 0 | 0 | 0 |
| Sodium High, Grade 1 | 0 | 2 | 2 | 0 | 0 | 0 |
| Sodium High, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium High, Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium High, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium Low, Grade 1 | 11 | 7 | 4 | 9 | 7 | 0 |
| Sodium Low, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium Low, Grade 3 | 1 | 1 | 3 | 3 | 0 | 1 |
| Sodium Low, Grade 4 | 0 | 0 | 0 | 0 | 1 | 0 |
| Total Bilirubin High, Grade 1 | 3 | 2 | 4 | 3 | 2 | 0 |
| Total Bilirubin High, Grade 2 | 0 | 0 | 1 | 4 | 0 | 0 |
| Total Bilirubin High, Grade 3 | 0 | 0 | 0 | 1 | 0 | 0 |
| Total Bilirubin High, Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urate High, Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urate High, Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urate High, Grade 3 | 5 | 7 | 4 | 9 | 4 | 0 |
| Urate High, Grade 4 | 3 | 0 | 0 | 2 | 0 | 0 |
Complete response rate is defined as the percentage of patients with CR
| Percentage of participants | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| Complete Response Rate | 70 (49.8 to 86.2) | 64 (40.7 to 82.8) | 75 (50.9 to 91.3) | 67 (43.0 to 85.4) | 30 (14.7 to 49.4) | 43 (9.9 to 81.6) |
Duration of CR per investigator was defined as the time from start of the first documentation of CR to the first documentation of tumor progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.
| Months | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| Duration of Complete Response | 7.4 (5.1 to NA) | NA (14.7 to NA) | NA (2.8 to NA) | NA (6.6 to NA) | NA (7.4 to NA) | NA (NA to NA) |
Duration of response per investigator was defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression (PD) based on radiographic evidence of progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.
| Months | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| Duration of Objective Response | 7.6 (5.1 to 67.7) | 46.0 (8.5 to NA) | NA (3.6 to NA) | NA (12.7 to NA) | 7.4 (7.4 to NA) | NA (11.3 to NA) |
Progression-free survival (PFS) per investigator was defined as the time from start of study treatment to first documentation of tumor progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.
| Months | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| Progression-free Survival | 8.6 (6.3 to 40.1) | 47.2 (10.8 to NA) | 32.5 (4.0 to NA) | NA (9.4 to NA) | 8.7 (5.1 to NA) | 10.5 (0.5 to NA) |
Disease control rate (DCR) per investigator was defined as the percentage of subjects with CR, PR, or SD, per investigator assessment of best clinical response per Cheson 2007. For Parts E and F, the assessment was per BICR.
| Percentage of participants | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| Disease Control Rate | 100 (87.2 to 100.0) | 95 (77.2 to 99.9) | 85 (62.1 to 96.8) | 90 (69.6 to 98.8) | 77 (57.7 to 90.1) | 57 (18.4 to 90.1) |
Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment.
| Percentage of participants | Part E | Part F |
|---|---|---|
| ORR According to Lugano Criteria Per BICR (Parts E and F) | 67 (47.2 to 82.7) | 43 (9.9 to 81.6) |
B symptom resolution rate per investigator was defined as the percentage of subjects with lymphoma-related B symptoms at baseline who achieved resolution of all B symptoms at any time during the treatment period.
| Percentage of participants | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| B Symptom Resolution Rate | 100 (47.8 to 100.0) | 100 (54.1 to 100.0) | 86 (42.1 to 99.6) | 67 (22.3 to 95.7) | 0 (NA to NA) | 0 (NA to NA) |
| Participants | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| Baseline Negative | 23 | 20 | 16 | 17 | 24 | 6 |
| Baseline Negative - Negative post-baseline | 14 | 12 | 5 | 12 | 17 | 6 |
| Baseline Negative - Positive post-baseline | 9 | 8 | 11 | 5 | 7 | 0 |
| Baseline Positive | 3 | 2 | 1 | 1 | 2 | 0 |
| Baseline Positive - Negative post-baseline | 3 | 2 | 1 | 1 | 2 | 0 |
| Baseline Positive: Treatment-boosted post-baseline | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Part D |
|---|---|
| Cycle 1 (Pre-dose nivolumab) | 0 |
| First Positive Cycle (pre-dose) - Cycle 2 | 4 |
| First Positive Cycle (pre-dose) - Cycle 8 | 1 |
| Any positive post-baseline | 5 |
Overall survival (OS) per investigator was defined as the time from date of enrollment to date of death due to any cause.
| Months | Part E | Part F |
|---|---|---|
| Overall Survival (Parts E and F Only) | 31.8 (14.8 to NA) | 12.6 (0.5 to NA) |
Collected over Non-serious Adverse Events, Serious Adverse Events, and All-Cause Mortality were followed for up to 122 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A | 13/27 (48.1%) | 5/27 (18.5%) | 27/27 (100%) |
| Part B | 9/22 (40.9%) | 4/22 (18.2%) | 22/22 (100%) |
| Part C | 12/20 (60%) | 13/20 (65%) | 20/20 (100%) |
| Part D | 4/21 (19%) | 4/21 (19%) | 21/21 (100%) |
| Part E | 10/30 (33.3%) | 14/30 (46.7%) | 27/30 (90%) |
| Part F | 5/7 (71.4%) | 4/7 (57.1%) | 7/7 (100%) |
| Event | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/27 | 0/22 | 0/20 | 0/21 | 0/30 | 1/7 |
| NauseaGastrointestinal disorders | 0/27 | 0/22 | 0/20 | 3/21 | 0/30 | 0/7 |
| VomitingGastrointestinal disorders | 0/27 | 0/22 | 0/20 | 3/21 | 0/30 | 0/7 |
| COVID-19Infections and infestations | 0/27 | 0/22 | 0/20 | 0/21 | 0/30 | 1/7 |
| PneumoniaInfections and infestations | 0/27 | 0/22 | 2/20 | 0/21 | 2/30 | 1/7 |
| Septic shockInfections and infestations | 0/27 | 0/22 | 1/20 | 0/21 | 0/30 | 1/7 |
| Urinary tract infectionInfections and infestations | 0/27 | 1/22 | 2/20 | 0/21 | 0/30 | 1/7 |
| Fibula fractureInjury, poisoning and procedural complications | 0/27 | 0/22 | 0/20 | 0/21 | 0/30 | 1/7 |
| Tibia fractureInjury, poisoning and procedural complications | 0/27 | 0/22 | 0/20 | 0/21 | 0/30 | 1/7 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 0/27 | 0/22 | 0/20 | 0/21 | 0/30 | 1/7 |
| Event | Part A | Part B | Part C | Part D | Part E | Part F |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 9/27 | 6/22 | 17/20 | 9/21 | 7/30 | 4/7 |
| Peripheral sensory neuropathyNervous system disorders | 21/27 | 17/22 | 8/20 | 10/21 | 14/30 | 4/7 |
| FatigueGeneral disorders | 12/27 | 10/22 | 10/20 | 16/21 | 9/30 | 1/7 |
| NauseaGastrointestinal disorders | 12/27 | 9/22 | 13/20 | 8/21 | 10/30 | 3/7 |
| ConstipationGastrointestinal disorders | 8/27 | 10/22 | 7/20 | 10/21 | 5/30 | 1/7 |
| Decreased appetiteMetabolism and nutrition disorders | 8/27 | 5/22 | 9/20 | 7/21 | 8/30 | 1/7 |
| Weight decreasedInvestigations | 6/27 | 5/22 | 5/20 | 4/21 | 4/30 | 3/7 |
| PyrexiaGeneral disorders | 2/27 | 4/22 | 7/20 | 7/21 | 2/30 | 0/7 |
| DehydrationMetabolism and nutrition disorders | 3/27 | 1/22 | 7/20 | 1/21 | 1/30 | 0/7 |
| ChillsGeneral disorders | 1/27 | 2/22 | 3/20 | 7/21 | 2/30 | 0/7 |
The Full Analysis Set includes all participants who received any amount of brentuximab vedotin.
| Age, Categorical(Participants) | Part A | Part B | Part C | Part D | Part E | Part F | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 1 | 4 | 1 | 1 | 12 |
| >=65 years | 25 | 19 | 19 | 17 | 29 | 6 | 115 |
| Sex: Female, Male(Participants) | Part A | Part B | Part C | Part D | Part E | Part F | Total |
|---|---|---|---|---|---|---|---|
| Female | 13 | 6 | 10 | 6 | 16 | 2 | 53 |
| Male | 14 | 16 | 10 | 15 | 14 | 5 | 74 |
| Ethnicity (NIH/OMB)(Participants) | Part A | Part B | Part C | Part D | Part E | Part F | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 0 | 1 | 2 | 2 | 11 |
| Not Hispanic or Latino | 25 | 18 | 20 | 20 | 28 | 5 | 116 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A | Part B | Part C | Part D | Part E | Part F | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 0 | 2 | 0 | 0 | 6 |
| White | 26 | 19 | 20 | 19 | 26 | 7 | 117 |
| More than one race | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 3 | 0 | 3 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Part A | Part B | Part C | Part D | Part E | Part F | Total |
|---|---|---|---|---|---|---|---|
| Grade 0 | 9 | 6 | 4 | 4 | 5 | 0 | 28 |
| Grade 1 | 12 | 9 | 12 | 16 | 10 | 4 | 63 |
| Grade 2 | 5 | 7 | 4 | 0 | 10 | 2 | 28 |
| Grade 3 | 1 | 0 | 0 | 0 | 5 | 1 | 7 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Missing | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2012 to primary completion in Apr 2023, 125 months.
Results were first posted in Jun 2024, 1 year 2 months after primary completion.
Of 206 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 111. This study's 125 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin